Evaluate the Beneficial Effects of an Oral Nutritional Supplement Based on Leonurus Cardiaca for the Improvement of Mood and Anxiety
In plain words A study of motherwort in people 20 to 50, run by Azienda di Servizi alla Persona di Pavia. It plans to enroll about 60 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 20 to 50. Conditions: General Anxiety Disorder.
- Aged 20 to 50 years
- Diagnosis of a generalised anxiety disorder (GAD), with manifestations occurring for >= 6 months that include excessive worry, poor concentration, restlessness, muscle tension, irritability, fatigue and difficulty sleeping
The exclusion criteria are on the listing.
What it tests, as registered
Leonurus cardiaca extract 250 mg; Placebo; Leonurus cardiaca extract 500 mg
Registered summary
This study aims to evaluate the efficacy and safety of Leonurus cardiaca extract in reducing anxiety symptoms in adults with Generalized Anxiety Disorder (GAD). Sixty drug-free participants aged 20-50 years with a diagnosis of GAD will be randomly assigned to receive either Leonurus cardiaca extract or placebo for 30 days. The primary outcome is the reduction in anxiety symptoms assessed by the SCAG scale. Secondary outcomes include changes in quality of life (SF-12), perceived stress (PSQ), anxiety severity (HAM-A), and anthropometric measures. The full summary is on the listing.
Where, as registered
No sites listed yet.